Business Wire
16 Oct 2026, 12:47 UTC · 1h ago
Research conducted at University of Michigan published in Anesthesia & Analgesia Practice demonstrates GE HealthCare End-tidal Control software may help to reduce fresh gas flow
Impact · against what's priced in
The clinical validation of GEHC's End-tidal Control software is a minor positive catalyst that supports a recovery in the PCS segment, which the market currently views as a drag on growth. While the study confirms product efficacy across 12,818 cases, the impact is marginal compared to the larger structural headwinds the stock is pricing in.
- GEHC+0.10
Challenges what's priced in





